Physician profile
William F Ryan
NPI 1497715189
$4,562.34
in general payments reported to CMS, 2019-2025
26 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $123 · 2021: $11.92 · 2022: $261 · 2023: $2,040 · 2024: $156 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $580 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $580.04 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $1,815.15 | 2019-2023 | |
| Astellas Pharma US INC | $449.68 | 2019-2025 | Padcev, Vyloy |
| Novartis Pharmaceuticals Corporation | $335.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $250.85 | 2019-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $250.20 | 2019-2022 | |
| Janssen Biotech, INC. | $213.15 | 2019 | |
| Merck Sharp & Dohme LLC | $172.98 | 2019 | |
| Depuy Synthes Sales INC. | $171.95 | 2023-2024 | Na, Va-Lcp |
| Madrigal Pharmaceuticals | $149.66 | 2025 | Rezdiffra |
| Pfizer INC. | $125.43 | 2019-2025 | |
| Amgen INC. | $108.30 | 2019-2023 | Lumakras |
| Eisai INC. | $101.49 | 2019 | |
| Exelixis INC. | $99.95 | 2024 | |
| Celgene Corporation | $63.12 | 2019-2022 | |
| Lilly USA, LLC | $41.71 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $41.57 | 2025 | Gore Viatorr Tips Endoprosthesis With Controlled Expansion |
| Bayer Healthcare Pharmaceuticals INC. | $27.17 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $22.82 | 2020 | |
| Genentech USA, INC. | $17.54 | 2022 | |
| Incyte Corporation | $17.16 | 2022 | |
| Glaxosmithkline, LLC. | $16.42 | 2022 | |
| Boston Scientific Corporation | $15.81 | 2023 | Eluvia |
| Morphosys, US INC. | $14.98 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.46 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.